This article is more than 5 years old. Information may no longer be current.

Discgenics includes cryopreservation media into cell therapy product

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BioLife Solutions Inc. announced that Discgenics Inc. has incorporated its CryoStor clinical grade cryopreservation freeze media in the development and potential commercialization of their Injectable Discogenic Cell Therapy product to treat patients with low back pain associated with degenerative disc disease.

“We evaluated CryoStor against traditional home brew and commercial freeze media cocktails. CryoStor provided excellent post-thaw cell viability, recovery and potency,” Bob Wynalek, chief operating and commercialization officer of Discgenics, stated in a company press release. “The serum-free, protein-free formulation, FDA drug master file, available technical support and current use numerous other clinical stage regenerative medicine companies all supported our decision to incorporate CryoStor into our production and delivery processes.”